| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G |
| 16 Nov 2026 | 10-Q |
| 16 Nov 2026 |
8-K: Results of Operations and Financial Condition
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: |
| 13 Nov 2026 | 10-Q/A |
| 13 Nov 2026 |
8-K: Non-Reliance on Previously Issued Financial Statements
On November 13, 2026, the Audit Committee of the Board of Directors (the “Audit Committee”) of Apnimed, Inc. (the “Company”), based on the recommendation of the Company’s management, concluded that the Company’s previously issued financi... |
| 04 Nov 2026 | SCHEDULE 13G |
| 08 Sep 2026 | S-8 |
| 08 Sep 2026 | 10-Q |
| 08 Sep 2026 |
8-K: Results of Operations and Financial Condition
U.S. Food and Drug Administration (“FDA”) Accepted the NDA for AD109, with a proposed proprietary name Oxnimbi™, and assigned a PDUFA target action date of February 28, 2027 |
| 07 Aug 2026 | SCHEDULE 13G |
| 06 Aug 2026 | SCHEDULE 13G |
| 05 Aug 2026 |
Form 4: Morningside Venture Investments Ltd, 10% owner
Received 6,915,837 shares by conversion · Disposed of 6,915,837 shares (Other Transaction) · Acquired 6,915,837 shares (Other Transaction) · 1 more |
| 05 Aug 2026 |
Form 4: Alpha Wave Ventures GP, Ltd, 10% owner and 3 others
Received 7,054,956 shares by conversion |
| 03 Aug 2026 |
Form 4: Kelly Michael B, Chief Financial Officer
Disposed of 333,580 Stock Option (Right to Buy) (Disposition to Issuer) · Granted 333,580 Stock Option (Right to Buy) · Granted 31,434 Stock Option (Right to Buy) · 2 more |
| 03 Aug 2026 |
Form 4: Lind Kevin Robert, Director
Granted 108,916 Stock Option (Right to Buy) · Disposed of 1,369,322 Stock Option (Right to Buy) (Disposition to Issuer) · Granted 1,369,322 Stock Option (Right to Buy) |
| 03 Aug 2026 |
Form 4: Fonteyne Paul R., Director
Granted 44,477 Stock Option (Right to Buy) · Disposed of 140,844 Stock Option (Right to Buy) (Disposition to Issuer) · Granted 140,844 Stock Option (Right to Buy) |
| 03 Aug 2026 |
Form 4: Sender Gary, Director
Granted 44,477 Stock Option (Right to Buy) · Disposed of 140,844 Stock Option (Right to Buy) (Disposition to Issuer) · Granted 140,844 Stock Option (Right to Buy) |
| 03 Aug 2026 |
Form 4: Sekhri Paul J, Director
Granted 177,796 Stock Option (Right to Buy) · Bought 12,500 shares ($200K) · Disposed of 191,706 Stock Option (Right to Buy) (Disposition to Issuer) · 2 more |
| 03 Aug 2026 |
Form 4: Jones William A Jr, Director
Granted 44,477 Stock Option (Right to Buy) · Acquired 44,477 Stock Option (Right to Buy) (Disposition to Issuer) · Granted 44,477 Stock Option (Right to Buy) |
| 03 Aug 2026 |
Form 4: Miller Lawrence G., Director
Returned 448,247 shares to the issuer · Received 448,247 shares as a grant or award · Received 10,845 shares by conversion · 2 more |
Loading...